Don't have an account?
WAUKESHA, Wis., April 18, 2019 – GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration of its Deep Learning Image Reconstruction engine on its new Revolution Apex CT device and as an upgrade to its Revolution CT system in the United States.
“We are proud to usher in the next generation of image reconstruction,” said Mike Barber, President and CEO of MICT, GE Healthcare. “Our Deep Learning Image Reconstruction engine combines the ground truth image quality of filtered back projection (FBP) with the low dose capabilities of iterative reconstruction to produce TrueFidelityTM CT Images. These images offer outstanding image quality and restore noise texture to improve radiologists’ confidence in diagnosing a wide range of clinical cases.”
Deep Learning Image Reconstruction (DLIR) is the next generation image reconstruction option that uses a dedicated Deep Neural Network (DNN) to generate TrueFidelity CT Images. These TrueFidelity CT Images have the potential to improve reading confidence in a wide range of clinical applications such as head, whole body and cardiovascular, for patients of all ages.
Compared to current iterative reconstruction technology, TrueFidelity CT Images can elevate every image to a powerful first impression with impressive image quality performance1, and preferred image sharpness and noise texture2, without compromising dose performance.
“Physicians that have reviewed our new TrueFidelity CT Images consistently say they are among the best CT images they have ever seen, and our 510(k)-reader study also demonstrated this improvement,” said Scott Schubert, General Manager of Global Premium CT, GE Healthcare. “Revolution Apex delivers CT technology innovations including the Quantix™ 160 x-ray tube and Deep Learning Image Reconstruction, and we are pleased to bring these innovations as optional upgrades to our Revolution CT users as well.”
The FDA also granted 510(k) clearance to three additional GE Healthcare CT applications recently introduced at RSNA 2018: Bone VCAR, Thoracic VCAR with GSI Pulmonary Perfusion, and SnapShot Freeze 2.
Both Bone VCAR and SnapShot Freeze 2 are Edison applications. Edison is a platform that helps accelerate the development and adoption of AI technology and empower providers to deliver faster, more precise care.
Bone VCAR uses a deep-learning algorithm to automatically identify and label the vertebrae for faster spine assessment and improve reporting efficiency. SnapShot Freeze 2 is an intelligent motion correction algorithm that takes cardiac imaging to the next level by expanding the breadth of intelligent motion correction applications, further enhancing clinical performance and introducing whole heart motion correction.
Thoracic VCAR with GSI Pulmonary Perfusion provides automated segmentation and measurements for assessment and follow-up of thoracic diseases. It also now includes dedicated GSI Pulmonary Perfusion, a one-click protocol to assist in the identification of variations of relative perfusion distribution in the lungs. Thoracic diseases that may be associated with changes in perfusion include pulmonary embolism or chronic obstructive pulmonary disease (COPD).
###
Media Contact:
Margaret Steinhafel
Margaret.Steinhafel@ge.com
+1 608 381 8829
This press release is GE HealthCare historical archive material. Any reference in these materials to GE HealthCare products or their uses may not reflect current medical knowledge or up to date documentation for the products. Do not rely upon this release as a source of information on the safety or effectiveness of the products or on the contents of any product label or manual. Please refer to the current product documentation, including product labels and manuals, for current product information.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.